Early Adverse Events and Immune Response Following Second and Third COVID-19 Vaccination in Pregnancy
, Yoav Yinon 1,2,*, Ravit Peretz-Machluf 1,2, Omri Segal 1,2, Noam Regev 1,2, Keren Asraf 3, Ram Doolman 3, Yonatan Kubani 3, Tal Gonen 4, Gili Regev-Yochay 2,4 and Shiran Bookstein Peretz 1,2
Round 1
Reviewer 1 Report
Authors have reported safety of booster dose of COVID Vaccination in pregnancy. Immmunogenicty & minor side effects have been highlighted in study.
Whether any ethical issues or serious sided effects were noticed in recipients? this point needs to be clarified
Author Response
Thank you for your comment. None of the women in our study have experienced serious side effects. A clarification has been added to the results section as follows: "Of note, none of the pregnant women in both groups experienced serious side effects such as Myocarditis, Anaphylaxis or Bell's Palsy" (page 3, lines 110-112), and to the discussion section as follows: "Our results show that there were no additional adverse effects, including serious adverse effects…" (page 4, line 152). A mention of myocarditis and anaphylaxis has also been added to Table 2 (page 3, line 135).
Reviewer 2 Report
I read with great interests the article “Early Adverse Events and Immune Response Following 2nd
and 3rd COVID-19 Vaccination in Pregnancy”. The article is well written and the study seems well conducted. However, it comments very shortly a field of great scientific production in the last year (as the short reference list shows), and therefore I suggest the authors to implement the discussion with the following hints:
- important studies evaluating response to SARS COV 2 vaccine in pregnant women
(Am J Obstet Gynecol. 2021. doi:10.1016/j.ajog.2021.03.023;
JAMA. 2021;325:2370-2380. doi:10.1001/jama.2021.7563)
- the admission that guidelines already advised in favor of booster doses (Am J Obstet Gynecol MFM. 2022;4(5):100654. doi:10.1016/j.ajogmf.2022.100654)
- a very recent and updated review considering perinatal outcomes following vaccination
(Int J Gynecol Obstet. 2022;00:1-11. doi: 10.1002/ijgo.14336)
- the need for implementing counselling with these results, in view of the low acceptance rate of vaccines in pregnant women (Eur J Obstet Gynecol Reprod Biol. 2022;268:144-164. doi:10.1016/j. ejogrb.2021.12.003)
Author Response
Please see the attachment
Author Response File: 
Author Response.docx
